These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33125428)

  • 1. Effects of calcium-containing phosphate binders on cardiovascular events and mortality in predialysis CKD stage 5 patients.
    Tsai PH; Chung CH; Chien WC; Chu P
    PLoS One; 2020; 15(10):e0241435. PubMed ID: 33125428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of calcium-containing phosphate binders in incident U.S. dialysis patients.
    Winkelmayer WC; Liu J; Kestenbaum B
    Clin J Am Soc Nephrol; 2011 Jan; 6(1):175-83. PubMed ID: 20947790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of calcium on cardiovascular events in patients with kidney disease and in a healthy population.
    West SL; Swan VJ; Jamal SA
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S41-7. PubMed ID: 20089502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E; Tuñón J; Egido J; Ortiz A
    Cardiovasc Pathol; 2012; 21(5):372-81. PubMed ID: 22425627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
    Negri AL
    J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
    Tseng WC; Liu JS; Hung SC; Kuo KL; Chen YH; Tarng DC; Hsu CC
    Int J Cardiol; 2017 Jul; 238():72-78. PubMed ID: 28363684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium loading, calcium accumulation, and associated cardiovascular risks in dialysis patients.
    Klemmer PJ
    Blood Purif; 2005; 23 Suppl 1():12-9. PubMed ID: 15832018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
    Spasovski G
    Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis.
    Spoendlin J; Paik JM; Tsacogianis T; Kim SC; Schneeweiss S; Desai RJ
    JAMA Intern Med; 2019 Jun; 179(6):741-749. PubMed ID: 31058913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon.
    Qunibi WY; Nolan CA; Ayus JC
    Kidney Int Suppl; 2002 Dec; (82):S73-80. PubMed ID: 12410860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketoanalogue supplements reduce mortality in patients with pre-dialysis advanced diabetic kidney disease: A nationwide population-based study.
    Chen HY; Sun CY; Lee CC; Wu IW; Chen YC; Lin YH; Fang WC; Pan HC
    Clin Nutr; 2021 Jun; 40(6):4149-4160. PubMed ID: 33597108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanisms of hyperphosphatemia-induced vascular calcification.
    Cozzolino M; Gallieni M; Brancaccio D
    Int J Artif Organs; 2008 Dec; 31(12):1002-3. PubMed ID: 19115191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease.
    Ogata H; Sugawara H; Yamamoto M; Ito H
    J Atheroscler Thromb; 2024 Jan; 31(1):1-14. PubMed ID: 37766573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.